<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Neutralizing monoclonal antibodies against SARS-CoV</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>NMAb’s name</th>
    <th>Type</th>
    <th>Source</th>
    <th>Preparation</th>
    <th>Target</th>
    <th>Assay and result</th>
    <th>Ref.</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="2">80R</td>
    <td rowspan="2">sdAb</td>
    <td rowspan="2">Human</td>
    <td rowspan="2">Nonimmune phage libraries of human antibodies</td>
    <td rowspan="2">324–503</td>
    <td>LV neutralization: IC
     <sub>50</sub> &lt; 7.43 nM;
    </td>
    <td rowspan="2">
     <sup>
      <xref ref-type="bibr" rid="CR13">13</xref>,
      <xref ref-type="bibr" rid="CR14">14</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td>Full protection of mice: 4/4 mice with &gt;4 log reduction in lung viral load at 12.5 mg/kg.</td>
   </tr>
   <tr>
    <td rowspan="2">CR3014</td>
    <td rowspan="2">scFv</td>
    <td rowspan="2">Human</td>
    <td rowspan="2">Semisynthetic antibody phage display libraries</td>
    <td rowspan="2">318–510</td>
    <td>LV neutralization: ND
     <sub>100</sub> at 42 nM;
    </td>
    <td rowspan="2">
     <sup>
      <xref ref-type="bibr" rid="CR15">15</xref>,
      <xref ref-type="bibr" rid="CR16">16</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td>Protection of ferrets: 10 mg/kg.</td>
   </tr>
   <tr>
    <td rowspan="2">
     <p>1A5</p>
     <p>2C5</p>
    </td>
    <td rowspan="2">IgG</td>
    <td rowspan="2">Mouse</td>
    <td rowspan="2">Animal immunization; hybridoma technology</td>
    <td rowspan="2">310–535</td>
    <td>LV neutralization: IC
     <sub>50</sub> = 0.71 µg/ml.
    </td>
    <td rowspan="2">
     <sup>
      <xref ref-type="bibr" rid="CR17">17</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td>LV neutralization: IC
     <sub>50</sub> = 1.27 µg/ml.
    </td>
   </tr>
   <tr>
    <td>S230.15</td>
    <td>IgG</td>
    <td>Human</td>
    <td>B cell-based EBV transformation</td>
    <td>RBD</td>
    <td>Full protection of mice: 200 μg/mouse.</td>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR18">18</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td rowspan="3">m396</td>
    <td rowspan="3">IgG1</td>
    <td rowspan="3">Human</td>
    <td rowspan="3">Healthy human antibody libraries of volunteers</td>
    <td rowspan="3">482–491</td>
    <td>LV (GD03) neutralization: IC
     <sub>50</sub> = 0.1 µg/ml;
    </td>
    <td rowspan="3">
     <sup>
      <xref ref-type="bibr" rid="CR18">18</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td>LV (Tor2) neutralization: IC
     <sub>50</sub> = 0.01 µg/ml;
    </td>
   </tr>
   <tr>
    <td>Full protection of mice: 200 μg/mouse.</td>
   </tr>
   <tr>
    <td rowspan="2">201</td>
    <td rowspan="2">IgG1</td>
    <td rowspan="2">Human</td>
    <td rowspan="2">
     <p>Transgenic mice;</p>
     <p>hybridoma technology</p>
    </td>
    <td rowspan="2">490–510</td>
    <td>LV neutralization: IC
     <sub>50</sub> ∼ 1 nM;
    </td>
    <td rowspan="2">
     <sup>
      <xref ref-type="bibr" rid="CR20">20</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td>Full protection of mice: 40 mg/kg.</td>
   </tr>
   <tr>
    <td>chimeric F26G18</td>
    <td>IgG</td>
    <td>Chimeric antibody</td>
    <td>Animal immunization; hybridoma technology</td>
    <td>460–476</td>
    <td>LV neutralization: titer = 2.07 nM.</td>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR22">22</xref>,
      <xref ref-type="bibr" rid="CR23">23</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td>341 C</td>
    <td>IgG</td>
    <td>Mouse</td>
    <td>Animal immunization; hybridoma technology</td>
    <td>490–510</td>
    <td>LV neutralization: ND
     <sub>100</sub> at a dilution of 1:1280.
    </td>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR24">24</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td>VHH-72</td>
    <td>sdAb</td>
    <td>llama</td>
    <td>Animal immunization and sequencing</td>
    <td>RBD</td>
    <td>PsV neutralization: IC
     <sub>50</sub> = 0.14 µg/ml.
    </td>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR25">25</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td>CR3022</td>
    <td>scFv</td>
    <td>Human</td>
    <td>Semisynthetic antibody phage display libraries</td>
    <td>RBD</td>
    <td>LV neutralization: IC
     <sub>100</sub> = 23.5 µg/ml.
    </td>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR26">26</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td rowspan="2">47D11</td>
    <td rowspan="2">IgG</td>
    <td rowspan="2">Chimeric antibody</td>
    <td rowspan="2">
     <p>Transgenic mice;</p>
     <p>hybridoma technology</p>
    </td>
    <td rowspan="2">RBD</td>
    <td>PsV neutralization: IC
     <sub>50</sub> = 0.061 μg/ml;
    </td>
    <td rowspan="2">
     <sup>
      <xref ref-type="bibr" rid="CR27">27</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td>LV neutralization: IC
     <sub>50</sub> = 0.19 μg/ml.
    </td>
   </tr>
   <tr>
    <td>S309</td>
    <td>IgG</td>
    <td>human</td>
    <td>Peripheral blood of SARS-infected patients</td>
    <td>the front end of RBD</td>
    <td>PsV neutralization: IC
     <sub>50</sub> = 120 ~ 180 ng/ml.
    </td>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR28">28</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td>ADI-55689</td>
    <td rowspan="8">IgG</td>
    <td rowspan="8">Human</td>
    <td rowspan="8">Memory B cell repertoire of a convalescent SARS donor</td>
    <td rowspan="8">RBD</td>
    <td rowspan="8">PsV neutralization: IC
     <sub>50</sub> = 0.004 ~ 0.06 μg/ml.
    </td>
    <td rowspan="8">
     <sup>
      <xref ref-type="bibr" rid="CR41">41</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td>ADI-55993</td>
   </tr>
   <tr>
    <td>ADI-56000</td>
   </tr>
   <tr>
    <td>ADI-55688</td>
   </tr>
   <tr>
    <td>ADI-56046</td>
   </tr>
   <tr>
    <td>ADI-56010</td>
   </tr>
   <tr>
    <td>ADI-55690</td>
   </tr>
   <tr>
    <td>ADI-55951</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>PsV</italic> pseudovirus, 
   <italic>LV</italic> live virus
  </p>
 </table-wrap-foot>
</table-wrap>
